Bridgeway Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Bridgeway Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-36,800	Closed	-$275K	–	1554
2015 Q2	$275K	Sell	36,800 -74,300	-67%	-$450K	0.01%	1275
2015 Q1	$664K	Sell	111,100 -3,132	-3%	-$19.7K	0.01%	974
2014 Q4	$864K	Hold	114,232	–	–	0.02%	825
2014 Q3	$593K	Hold	114,232	–	–	0.02%	997
2014 Q2	$492K	Buy	114,232 +38,700	+51%	+$148K	0.01%	1104
2014 Q1	$309K	Buy	75,532 +3,132	+4%	+$16K	0.01%	1237
2013 Q4	$386K	Hold	72,400	–	–	0.01%	1155
2013 Q3	$363K	Hold	72,400	–	–	0.01%	1164
2013 Q2	$323K	Buy	+72,400	New	+$325K	0.01%	1140

Other funds holding PGNX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bridgeway Capital Management's PGNX Position: Q3 2015 in Review

Bridgeway Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2015, closing a stake of 36,800 shares — an estimated $275K sold.

Bridgeway Capital Management first reported a position in PGNX in Q2 2013 and held it in 9 quarters. The position peaked at $864K in Q4 2014. 133 funds tracked by Wall St. Rank hold PGNX as of Q3 2015.

Bridgeway Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2015 after selling out during the quarter.
Bridgeway Capital Management sold 36,800 Progenics Pharmaceuticals Inc shares in Q3 2015, an estimated $275K.
Bridgeway Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 9 quarters.
Bridgeway Capital Management's Progenics Pharmaceuticals Inc position peaked at $864K in Q4 2014.
133 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2015.

Based on Bridgeway Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.